Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03837756
Registration number
NCT03837756
Ethics application status
Date submitted
7/02/2019
Date registered
12/02/2019
Date last updated
23/05/2023
Titles & IDs
Public title
Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV
Query!
Scientific title
Combining a TLR9 Agonist With Broadly Neutralizing Antibodies for Reservoir Reduction and Immunological Control of HIV Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial.
Query!
Secondary ID [1]
0
0
2018-001165-16
Query!
Secondary ID [2]
0
0
TITAN-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TITAN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HIV-1-infection
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Saline
Treatment: Drugs - Lefitolimod
Treatment: Drugs - 3BNC117 and 10-1074
Placebo Comparator: Arm A: Placebo/Placebo - This arm will receive placebo (sterile saline) for both Lefitolimod and 3BNC117 + 10-1074.
Active Comparator: Arm B: Lefitolimod/Placebo - This arm will receive Lefitolimod and placebo (sterile saline) for 3BNC117 + 10-1074.
Active Comparator: Arm C: Placebo/3BNC117 + 10-1074 - This arm will receive 3BNC117 + 10-1074 and placebo (sterile saline) for Lefitolimod.
Active Comparator: Arm D: Lefitolimod/3BNC117 + 10-1074 - This arm will receive both Lefitolimod and 3BNC117 + 10-1074.
Treatment: Drugs: Saline
Placebo
Treatment: Drugs: Lefitolimod
A TLR9 agonist administered s.c. once weekly for 8 weeks.
Treatment: Drugs: 3BNC117 and 10-1074
Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to re-initiation of cART during analytical treatment interruption (ATI)
Query!
Assessment method [1]
0
0
Time from date of cART cessation to the date of the last of three consecutive plasma HIV-1 RNA measurements >10,000 copies/mL, CD4 cell count <350 on two consecutive measurements, or end of ATI (i.e. 26 weeks after cessation of cART) - whichever comes first.
Query!
Timepoint [1]
0
0
Up to 26 weeks.
Query!
Secondary outcome [1]
0
0
Safety and Tolerability assessment measured by AEs, Adverse Reactions (ARs), SAEs,
Query!
Assessment method [1]
0
0
Subject who receives at least one dose of the IMP(s) will be included in the evaluation for safety, measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs) and (SUSAR)
Query!
Timepoint [1]
0
0
Duration of the study
Query!
Secondary outcome [2]
0
0
Plasma HIV RNA doubling time
Query!
Assessment method [2]
0
0
Plasma HIV RNA doubling time from first measurement >50 copies/mL to first measurement >1,000 copies/mL during the analytical treatment interruption (plasma HIV RNA measured by standard clinical assays, e.g. Cobas TaqMan; Lower limit of quantitation 20 copies/mL)
Query!
Timepoint [2]
0
0
Duration of ATI (up to 26 weeks)
Query!
Eligibility
Key inclusion criteria
- Documented HIV-1 infection
- Adults age 18-65 years
- On ART for a minimum of 18 months.
- CD4+ T cell count >500 at screening
- HIV-1 RNA plasma level of < 50 copies/mL by standard assays for at least 15 months (a
single viral load measurement > 50 but < 500 copies/mL during this time period is
allowable).
- Able to give informed consent
- Viral reservoir sensitivity to 3BNC117 and 10-1074. (Sensitivity of the viral
reservoir to neutralization by 3BNC117 and 10-1074 will be tested following the
screening visit (i.e. prior to randomization)).
Sensitivity of the viral reservoir to neutralization by 3BNC117 and 10-1074 will be tested
following the screening visit (i.e. prior to enrollment and randomization). Isolated PBMCs
will be analyzed using the PhenoSense HIV mAb Assay, Monogram Biosciences. The sensitivity
of an individuals archieved proviruses to bNAb neutralization will be determined by the
IC50 value of PBMC derived pseudovirus inhibition. Subjects that are considered sensitive
to both 3BNC117 (IC90<=1.5 µg/mL) and 10-1074 (IC90<=2.0 µg/mL) AND MPI>97 AND fulfill the
other inclusion/exclusion criteria will proceed to study enrolment and randomization.
If sensitivity cannot be determined by the PhenoSense HIVmAb Assay, participants will be
screened for 3BNC117 and 10-1074 sensitivity using HIV env sequencing carried out in-house
(Aarhus, Denmark). The method was originally established and validated by Rockefeller
University that already has this method implemented. The method utilizes HIV-1 DNA envelope
sequencing and a mathematical prediction binding algoritm of known binding sites of the
antibodies. Based on the individual HIV env sequence, proviruses are categorized as
"sensitive" or "resistant". Subjects that are determined to be sensitive to both 3BNC117
and 10-1074 (defined as at least 90% of known sequences sensitive to either bNAb) AND
fulfill the other inclusion/exclusion criteria will proceed to study enrolment and
randomization.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Any significant acute medical illness requiring hospitalization in the past 4 weeks
- Any evidence of an active AIDS-defining opportunistic infection
- Any condition that, in the Investigator's opinion, will prevent adequate compliance
with study therapy
- The following laboratory values at screening, the values can be repeated within the
screening period, but test results must be available before baseline (Day 0) and
checked for eligibility: Hepatic transaminases (AST or ALT) =3 x upper limit of normal
(ULN) // Serum total bilirubin =3 ULN // Estimated glomerular filtration rate (eGFR)
=50 mL/min (based on serum creatinine) // Platelet count =100 x109/L // Absolute
neutrophil count =1x109/L
- Hepatitis B or C infection
- History of: Malignancy, excluding non-melanoma skin cancers, or organ transplantation
- Receipt of strong immunosuppressive or systemic chemotherapeutic agents within 28 days
prior to study entry
- Known resistance to >2 classes of ART
- Known hypersensitivity to the components of lefitolimod, 3BNC117, 10-1074 or their
analogues
- Pre-existing autoimmune or antibody-mediated diseases
- Women who are pregnant or breastfeeding, or unwilling/ unable to use an acceptable
method of contraception (if of child bearing potential)
- Males or females who are unwilling or unable to use barrier contraception during
sexual intercourse until plasma HIV-1 RNA is undetectable using standard assays
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Factorial
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
6/05/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
47
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Alfred Hospital and Monash University - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Utah
Query!
Country [2]
0
0
Denmark
Query!
State/province [2]
0
0
Aalborg
Query!
Country [3]
0
0
Denmark
Query!
State/province [3]
0
0
Aarhus
Query!
Country [4]
0
0
Denmark
Query!
State/province [4]
0
0
Copenhagen
Query!
Country [5]
0
0
Denmark
Query!
State/province [5]
0
0
Hvidovre
Query!
Country [6]
0
0
Denmark
Query!
State/province [6]
0
0
Odense
Query!
Country [7]
0
0
Norway
Query!
State/province [7]
0
0
Oslo
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
University of Aarhus
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Aalborg University Hospital
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Odense University Hospital
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
Rigshospitalet, Denmark
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
Hvidovre University Hospital
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Other
Query!
Name [5]
0
0
The Peter Doherty Institute for Infection and Immunity
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Other collaborator category [6]
0
0
Other
Query!
Name [6]
0
0
University of Utah
Query!
Address [6]
0
0
Query!
Country [6]
0
0
Query!
Other collaborator category [7]
0
0
Other
Query!
Name [7]
0
0
Oslo University Hospital
Query!
Address [7]
0
0
Query!
Country [7]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074
in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1
reservoir
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03837756
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Ole S Søgaard, MD PhD
Query!
Address
0
0
Aarhus University Hospital
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03837756
Download to PDF